Completed PHASE4 INTERVENTIONAL 2-arm NCT01316718

Mesalazine for the Treatment of Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D) (MIBS)

Efficacy and Mode of Action of Mesalazine in the Treatment of Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D).

Sponsor: National Institute for Health Research, United Kingdom

Conditions Irritable Bowel Syndrome With Diarrhoea

Updated 5 times since 2017 Last updated: Jan 16, 2014 Started: Mar 31, 2011 Primary completion: Sep 30, 2013 Completion: Sep 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Irritable Bowel Syndrome With Diarrhoea and is currently completed. National Institute for Health Research, United Kingdom leads this study, which shows 5 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Mar 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute for Health Research, United Kingdom
University of Nottingham

Data source: University of Nottingham

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nottingham, United Kingdom